Admin Control Panel

New Post | Settings | Change Layout | Edit HTML | Edit posts | Sign Out


March20 podcast Dr Hazen
anti-TMA pill in a year or 2 ? (scroll 12 mins)

Additional info:
MEBO Karen
at UK Findacure conf 2020

Scroll down and select country

MEBO Map Testing & Meetups

Full details :
want listed ? contact

MEBO - UBIOME study 2018



MEBO Gut Microbiome Study
"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"
Funded by uBiome Research Grant

"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"

Dynamics of the Gut Microbiota in
Idiopathic Malodor Production

Started May 2018 - Ongoing

Current people sent kits : 100/100
3 kits per person


Participation info : LINK English

MEBO Private Facebook Group
to join : go to
or contact
Join/Watch the weekly
BO Sufferers Podcasts



TMAU Petition world
TMAU UK end total:262
TMAU UK ends 23/01/20
TMAU Petition USA end total 204
USA : Moveon open
TMAU (Dominican)
Metabolomic Profiling Study

Start : Aug 2016
Stage 1 : 27 Canadian volunteers to test
Latest click here (26 oct) :
17 samples returned

Note : Stage 1 is Canada only.
Return cut-off date : passed
Analysis can take 6/8 weeks
Analysis start in/before Nov
MEBO Research is a
NORD Member Organization
See RareConnect TMAU

Popular Posts (last 30 days)

Upcoming get-togethers

Let us know if you want a meetup listed
Follow MeBOResearch on Twitter

Blog Archive

MEBO Metabolic Malodor Survey (international) for Dr Hazen click here
click to Read more/less

survey for ANYONE who identifies with METABOLIC MALODOR

begun : Oct20
end : no ending for now

Regular readers will know that Dr Stan Hazen et al at Cleveland Clinic are developing a TMA-blocker pill, as they proposed in a 2011 paper that TMAO is a factor in CVD. Recently Dr Hazen and colleagues contacted MEBO as they have always thought they could also help with TMAU. This survey is to give them an idea of the 'state of the community'. It is a "version 1". They may not even look (though they have access permission), but it could be useful to give them an overview of the community

MEBO had a zoom call with Dr Hazen and his team in October. Another zoom call is planned when they have time

This is a GOOGLE FORMS survey

short url for survey :

current participants : 113 (update 18dec20)

Friday, September 27, 2013

Webinar : Social Security Administration's Compassionate Allowances initiative

The Social Security Administration (SSA), considers TMAU a "severe impairment" listed under section 5.05 in SSA impairments. However; SSA will not grant a disability payment on TMAU alone, rather there needs to be a "mental" disorder as well.
Cheryl L. Fields, MBA, Ph.D. (ABD)
Human Resources Consultant
MEBO US Community Outreach Director

The following is a webinar hosted by the USA charity the National Office for Rare Disorders (NORD)

"On Wednesday, Sept. 18th, NORD hosted a teleconference on the Social Security Administration's Compassionate Allowances initiative. Peter Smith, a policy analyst with the SSA, provided an overview of this initiative and responded to NORD member questions, such as how SSA identifies diseases to add to the list and how patient organizations can provide input in this process."

The webinar can be watched below or on the NORD website : SSA CAL webinar

MEBO Research have previously submitted Trimethylaminuria to be added to the list of disorders on the Compassionate Allowance List, but it was rejected. MEBO are resubmitting a new request for TMAU.

The following is a quote from the accompanying email newsletter sent by NORD about the webinar :
We have received several questions from members on how to add their disease to the Compassionate Allowances list (CAL).  SSA has developed the list with significant input from a series of public hearings and information submitted by advocacy groups, medical and scientific experts, and others.  NIH has provided scientific guidance to SSA in this process.  A primary consideration is whether conditions meet the SSA definition of a disability.  That definition can be found here.
On the webinar, in response to a question from a NORD member about how to submit a disease for consideration for the CAL, the SSA team recommended using the format employed by SSA in its impairment summaries of diseases currently on the list.
To view these summaries, click on any disease name on the current list of Compassionate Allowances diseases.
For example, view the impairment summary for Acute Leukemia.
Members who have additional questions after viewing the webinar are encouraged to contact the Compassionate Allowances Team at
NORD website :

A Public Charity
MEBO Research (em português)
MEBO's Blog (English)
El Blog de MEBO (español)

A EURORDIS and NORD Member Organization 


Post a Comment